Glycylcycline
|
WikiDoc Resources for Glycylcycline |
|
Articles |
|---|
|
Most recent articles on Glycylcycline Most cited articles on Glycylcycline |
|
Media |
|
Powerpoint slides on Glycylcycline |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Glycylcycline at Clinical Trials.gov Trial results on Glycylcycline Clinical Trials on Glycylcycline at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Glycylcycline NICE Guidance on Glycylcycline
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Glycylcycline Discussion groups on Glycylcycline Patient Handouts on Glycylcycline Directions to Hospitals Treating Glycylcycline Risk calculators and risk factors for Glycylcycline
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Glycylcycline |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Glycylcyclines are a new class of antibiotics derived from tetracycline. These tetracycline analogues are specifically designed to overcome two common mechanisms of tetracycline resistance, namely resistance mediated by acquired efflux pumps and/or ribosomal protection. Presently, there is only one glycylcycline antibiotic for clinical use: tigecycline.
History
The development of these agents was spurred by the increasing prevalence of bacteria resistant to tetracyclines. These agents were first synthesized in the early 1990's by making modifications to the tetracyclines. By adding a bulky N,N-dimethylglycylamido side chain to position 9 of minocycline, the compound became less susceptible to tetracycline resistance mediated by acquired efflux pumps and/or ribosomal protection. Further development of this initial work led to the creation of tigecycline, the first glycylcycline available for clinical use.
Mechanism of Action
Glycylcycline antibiotics have a similar mechanism of action as tetracycline antibiotics. Both classes of antibiotics bind to the 30S ribosomal subunit to prevent the amino-acyl tRNA from binding to the A site of the ribosome. However, the glycylcyclines appear to bind more effectively than the tetracyclines [1].
Mechanisms of Resistance
While glycylcyclines have greater efficacy against organisms with tetracycline resistance mediated by acquired efflux pumps and/or ribosomal protection, the glycylcyclines are not effective against organisms with chromosomal efflux pumps, such as Pseudomonas and Proteeae[2].
Side Effects and Contraindications
Since glycylcyclines are similar to tetracyclines, they share many of the same side effects and contraindications as tetracyclines. These side effects may include nausea/vomiting, headache, photosensitivity, discoloration of growing teeth, and fetal damage.
These antibiotics should not be given to pregnant women due to risk of fetal harm. Additionally, these drugs should not be administered during periods of tooth development because of the risk of tooth discoloration. Due to glycylcyclines' similarities with tetracyclines, hypersensitivity reactions to tetracycline antibiotics may predispose one to hypersensitivity reactions with glycylcycline antibiotics; hence, glycylcyclines should be used with caution in these patients.
References
- Tigecycline: A novel glycylcycline antiobiotic. Aug 1, 2005. By: Kara L. Smith, BSc, Sarah M. McCabe, BSc, Jeffrey R. Aeschlimann, PharmD. Formulary.
External links
- Tygacil (tigecycline IV) manufacturer website.
- Zhanel GG, Homenuik K, Nichol K; et al. (2004). "The glycylcyclines: a comparative review with the tetracyclines". Drugs. 64 (1): 63–88. PMID 14723559.